This past Thursday (July 19, 2012), the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) conditionally approved marketing authorization for the drug crizotinib (Xalkori) to treat adults with previously anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Despite known side effects (vision disorder, nausea, diarrhea, vomiting, edema, constipation, and fatigue) associated with this drug, the CHMP points that with an objective response rate of 60%, and median progression free survival of 9.2 months, "there is a favorable benefit-to-risk balance for crizotinib."
To read more about this research, click here.
No comments:
Post a Comment